A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 27-37

  Liu, Hao ^a   Chen, Anmin ^a   Guo, Fengjing ^a   Yuan, Lin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gene therapy; Human prostate cancer; Matrix metalloproteinase; Nuclear factor kappaB; Osteopontin

Indexed keywords

GELATINASE A; GELATINASE B; I KAPPA B KINASE; I KAPPA B KINASE 1; I KAPPA B KINASE 2; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; OSTEOPONTIN; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77953610434     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.012     Document Type: Article

References (52)

1. Buijs J.T., van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 2009, 273:177-193.
2. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 1999, 5:2271-2277.
3. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., Harris J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer 1997, 3:605-611.
4. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. J. Natl. Cancer Inst. 2002, 94:513-521.
5. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., Howitt R., West C.R. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002, 62:3417-3427.
6. Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F., Yeatman T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004, 10:184-190.
7. Rittling S.R., Chambers A.F. Role of osteopontin in tumour progression. Brit. J. Cancer 2004, 90:1877-1881.
8. Macrì A., Versaci A., Lupo G., Trimarchi G., Tomasello C., Loddo S., Sfuncia G., Caminiti R., Teti D., Famulari C. Role of osteopontin in breast cancer patients. Tumori 2009, 95:48-52.
9. Fong Y.C., Liu S.C., Huang C.Y., Li T.M., Hsu S.F., Kao S.T., Tsai F.J., Chen W.C., Chen C.Y., Tang C.H. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009, 64:263-270.
10. Zhang J., Takahashi K., Takahashi F., Shimizu K., Ohshita F., Kameda Y., Maeda K., Nishio K., Fukuchi Y. Differential osteopontin expression in lung cancer. Cancer Lett. 2001, 171:215-222.
11. Gong M., Lu Z., Fang G., Bi J., Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 2008, 272:148-159.
12. Jain A., McKnight D.A., Fisher L.W., Humphreys E.B., Mangold L.A., Partin A.W., Fedarko N.S. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin. Cancer Res. 2009, 15:5199-5207.
13. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., Chambers A.F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
14. Adwan H., Bauerle T.J., Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 2004, 11:109-120.
15. Adwan H., Bäuerle T., Najajreh Y., Elazer V., Golomb G., Berger M.R. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int. J. Oncol. 2004, 24:1234-1235.
16. Yamate T., Kohri K., Umekawa T., Iguchi M., Kurita T. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cell. J. Urol. 1998, 160:1506-1512.
17. Nemoto H., Rittling S.R., Yoshitake H., Furuya K., Amagasa T., Tsuji K., Nifuji A., Denhardt D.T., Noda M. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 2001, 16:652-659.
18. Wu Y., Denhardt D.T., Rittling S.R. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Brit. J. Cancer 2000, 83:156-163.
19. Desai B., Rogers M.J., Chellaiah M.A. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol. Cancer 2007, 6:18.
20. Weber G.F., Akshar S., Glimcher M.J., Cantor H. Receptor-Ligand interaction between CD44 and osteopontin (Eta-1). Science 1996, 271:509-519.
21. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., Mukherjee B.B., Li X.D., Mukherjee D.C., Seides S., Rosenberg J., Stark K., Mukherjee A.B. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 1997, 94:9308-9313.
22. Mi Z., Guo H., Russell M.B., Liu Y., Sullenger B.A., Kuo P.C. RNA Aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol. Ther. 2009, 17:153-161.
23. Desai B., Ma T., Zhu J., Chellaiah M.A. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J. Cell Biochem. 2009, 108:272-284.
24. Castellano G., Malaponte G., Mazzarino M.C., Figini M., Marchese F., Gangemi P., Travali S., Stivala F., Canevari S., Libra M. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin. Cancer Res. 2008, 14:7470-7480.
25. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappaB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 2001, 276:44926-44935.
26. Rangaswami H., Bulbule A., Kundu G.C. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/I kappaBalpha kinase-dependent nuclear factor kappa B-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 2004, 279:38921-38935.
27. Khodavirdi A.C., Song Z., Yang S., Zhong C., Wang S., Wu H., Pritchard C., Nelson P.S., Roy-Burman P. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006, 66:883-888.
28. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997, 278:860-866.
29. Wai P.Y., Mi Z., Guo H., Sarraf-Yazdi S., Gao C., Wei J., Marroquin C.E., Clary B., Kuo P.C. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005, 26:741-751.
30. Butler W.T. The nature and significance of osteopontin. Connect. Tissue Res. 1989, 23:123-136.
31. Hirama M., Takahashi F., Takahashi K., Akutagawa S., Shimizu K., Soma S., Shimanuki Y., Nishio K., Fukuchi Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003, 198:107-117.
32. Denhardt D.T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993, 7:1475-1482.
33. Naqvi A.R., Islan M.N., Choudhury N.R., Haq Q.M. The fascinating world of RNA interference. Int. J. Biol. Sci. 2009, 5:97-117.
34. Song J., Giang A., Lu Y., Pang S., Chiu R. Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep. 2008, 41:358-362.
35. Chang H. RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther. 2007, 14:677-685.
36. Haasnoot J., Westerhout E.M., Berkhout B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 2007, 25:1435-1443.
37. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
38. Dave R.S., Pomerantz R.J. RNA interference on the road to an alternate therapeutic strategy. Rev. Med. Virol. 2003, 13:373-385.
39. Tuck A.B., Hota C., Wilson S.M., Chambers A.F. Osteopontin induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003, 22:1198-1205.
40. Tuck A.B., Elliott B.E., Hota C., Tremblay E., Chambers A.F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell Biochem. 2000, 78:465-475.
41. Lin Y.H., Huang C.J., Chao J.R., Chen S.T., Lee S.F., Yen J.J., Yang-Yen H.F. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol. Cell Biol. 2000, 20:2734-2742.
42. Zhu B., Suzuki K., Goldberg H.A., Rittling S.R., Denhardt D.T., McCulloch C.A., Sodek J. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J. Cell Physiol. 2004, 198:155-167.
43. Teramoto H., Castellone M.D., Malek R.L., Letwin N., Frank B., Gutkind J.S., Lee N.H. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005, 24:489-501.
44. Das R., Mahabeleshwar G.H., Kundu G.C. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 2003, 278:28593-28606.
45. Ogata T., Ueyama T., Nomura T., Asada S., Tagawa M., Nakamura T., Takahashi T., Matsubara H., Oh H. Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2007, 359:341-347.
46. Das R., Mahabeleshwar G.H., Kundu G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol.Chem. 2004, 279:11051-11064.
47. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. New Engl. J. Med. 1997, 336:1066-1071.
48. Thompson J.E., Phillips R.J., Erdjument-Bromage H., Tempst P., Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 1995, 80:573-582.
49. Zhaodan C., William J.H., Xiong G. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996, 27:1128-1131.
50. Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., Baldwin A.S. I kappaB interacts with the nuclear localization sequences of the subunits of NF-kappaB: a mechanism for cytoplasmic retention. Genes Dev. 1992, 6:1899-1913.
51. Hay R.T., Vuillard L., Desterro J.M., Rodriguez M.S. Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha. Philos. Trans. Roy. Soc. Lond. B. Biol. Sci. 1999, 354:1601-1609.
52. Burke J.R., Strnad J. The catalytic subunits of IkappaB kinase, IKK-1 and IKK-2, Contain non-equivalent active sites when expressed as homodimers. Biochem. Biophys. Res. Commun. 2002, 293:1508-1513.